Screening trial for rare cancer gene changes in existing medicines
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial checks whether existing cancer medicines can help people whose tumors have specific “gene changes” (mutations). You may be assigned to a treatment arm that matches your tumor’s gene results after fresh biopsy and blood testing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have a confirmed advanced or metastatic cancer that has run out of standard options (or no effective standard option exists)
- Your tumor must have a rare “actionable” gene change (or a common cancer with a rare actionable gene change), found on validated genetic testing
- Have at least 3 months of expected life ahead and a doctor agrees you can do study visits and treatment
- Provide fresh tissue biopsy and required blood samples for research at the start of the study
- Be well enough to participate: adults usually need ECOG 0–1 (sometimes ECOG 2 allowed case-by-case), with similar age-based fitness scores for children/teens
- If you can become pregnant (or have a partner who can): agree to pregnancy prevention rules during the study and after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two targeted drugs (dabrafenib and trametinib) for patients whose cancer has a specific change in the BRAF gene called V600. These drugs work together to block signals that help the cancer grow. The trial is for children, teenagers, and adults with many types of cancer, except for a few common ones that already have approved treatments.
This trial tests whether combining two targeted cancer medicines—vemurafenib and cobimetinib—can treat adults whose tumors have a specific “BRAF V600” mutation. You may be screened with blood tests and a tissue biopsy before starting treatment.
This trial helps match people with advanced, hard-to-treat cancers to targeted cancer drugs based on lab testing of their tumor. It may help if standard treatment isn’t working or isn’t available, and if your tumor has a “targetable” genetic change.
This Phase 2 trial matches people with advanced cancer to a targeted treatment based on a genetic (DNA) or protein (IHC) test from their tumor. It’s for cancers that are no longer responding to standard treatment or where no standard option is available.
This study tests targeted drugs or immunotherapy based on the genetic features of your tumor. It may help people with rare, advanced cancers whose disease has progressed after standard treatment options.
This trial tests different targeted therapies based on the unique genetic changes in your tumor. It is for people with advanced or metastatic cancer who have exhausted standard options and whose tumor has specific genetic markers matched to one of the study drugs.
Hear when a new Haematological Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.